Search
Home
About Us
Management & Board of Directors
Scientific Advisors
Partners
Discovery Platform & Disease Targets
Primary MS-Related Fatigue
Cancer
Therapeutic Pipeline
MCT-125
MCT-465
MCT-475
MCT-485
Xenogenics Corp.
Investor Information
Investor Relations & Stock Information
SEC Filings & Annual Reports
Corporate Governance
News & Announcements
Contact, Careers & Legal
Contact Us
Careers
Legal
Sitemap
Company News and Filings
Xenogenics Received Rights to Polyanhydride Compounds Drug Delivery Patent
MultiCell Technologies Receives Final Payment Under QTDP Program
MULTICELL TECHNOLOGIES, INC. Financials
MULTICELL TECHNOLOGIES, INC. Files SEC form 10-Q, Quarterly Report
MULTICELL TECHNOLOGIES, INC. Files SEC form 10-Q, Quarterly Report
Company News and Filings